Search Result

Pathways Recommended:	Anti-infection

Results for "

Enterobacteriaceae infections

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (14) Bacterial (20) Beta-lactamase (6) Drug Metabolite (5) Isotope-Labeled Compounds (1) Penicillin-binding protein (PBP) (6) Reference Standards (2)
By Research Areas:	Cancer (2) Infection (20) Inflammation/Immunology (4)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164036

Lolamicin	Antibiotic Bacterial	Infection
Lolamicin is an orally effective inhibitor that specifically targets the Gram-negative bacteria lipoprotein transport system LolCDE complex. It selectively inhibits the transmembrane transport of outer membrane lipoproteins by competitively binding to lipoprotein binding sites. Lolamicin destroys the integrity of the bacterial outer membrane, leading to cell death, and has both bactericidal and antibacterial activity. It has significant effects on multidrug-resistant Enterobacteriaceae pathogens (such as Escherichia coli and Klebsiella pneumoniae). Lolamicin can be used to inhibit the study of acute pneumonia, sepsis and other infections caused by Gram-negative bacteria .

HY-W009168

Tazobactam sodium Maximum Cited Publications 18 Publications Verification	Bacterial Antibiotic	Infection Cancer
Tazobactam sodium is an antibiotic of the beta-lactamase inhibitor class. Ceftolozane combines with Tazobactam, extends the activity of ceftolozane against many ESBL-producing Enterobacteriaceae and some Bacteroides spp..

HY-111521

Meropenem-vaborbactam Carbavance	Antibiotic Bacterial Beta-lactamase	Infection
Meropenem-vaborbactam (Carbavance) is a Carbapenem Antibiotic and Boronic acid-based beta-lactamase inhibitor, is a fixed-dose combination product with potent in vitro activity against Enterobacteriaceae that are Klebsiella pneumoniae carbapenemase producers. Meropenem-vaborbactam exhibits activity against Pseudomonas aeruginosa isolates , with an MIC₅₀ of 0.5 μg/mL and an MIC₉₀ of 8 μg/mL .

HY-A0111

Cefetamet 1 Publications Verification Ro 15-8074; Deacetoxycefotaxime	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-157536

SMT-738	Bacterial	Infection Inflammation/Immunology
SMT-738 is a bacterial bactericide. SMT-738 targets the small molecules responsible for lipoprotein transport in Enterobacteriaceae, causing abnormal lipoprotein localization and bacterial cell death. SMT-738 inhibits the growth of E. coli and K. pneumoniae. SMT-738 reduces bacterial loads in mouse models of urinary tract infection, bloodstream infection, and pulmonary infection caused by Enterobacterales. SMT-738 can be used in the research of Enterobacteriaceae infections, urinary tract infections, bloodstream infections, and pneumonia .

HY-19936A

ACHN-975 TFA 1 Publications Verification	Bacterial	Infection
ACHN-975 TFA is a selective LpxC inhibitor and exhibits a subnanomolar LpxC inhibitory activity. ACHN-975 TFA is against a wide range of gram-negative bacterias with low MIC values (≤1 μg/mL) .

HY-16955A

Plazomicin sulfate 1 Publications Verification ACHN 490 sulfate	Antibiotic Bacterial	Infection
Plazomicin (ACHN 490) sulfate is a semi-synthetic aminoglycoside Antibiotic. Plazomicin sulfate acts as a substrate for Aminoglycoside acetyltransferase and Aminoglycoside phosphotransferase. Plazomicin sulfaten is not modified by various common aminoglycoside-modifying enzymes. Plazomicin sulfate selectively inhibits MATE2-K. Plazomicin sulfate exhibits activity against multidrug-resistant bacteria, including carbapenem-resistant Enterobacterales .

HY-W009168R

Tazobactam sodium (Standard)	Reference Standards Bacterial Antibiotic	Infection Cancer
Flutianil (Standard) is the analytical standard of Flutianil. This product is intended for research and analytical applications. Flutianil is a fungicide, which specifically inhibits the powdery mildew species. Flutianil inhibits the haustorium formation and subsequent mycelia growth .

HY-125604

WCK-4234	Beta-lactamase Bacterial	Infection Inflammation/Immunology
WCK-4234 is a diazabicyclooctane β-lactamase inhibitor and susceptibility restorer. WCK-4234 lacks direct antibacterial activity. WCK-4234 inhibits class A, C, D β-lactamases and extended-spectrum β-lactamases to potentiate Imipenem (HY-B1369A) and Meropenem (HY-13678) activity against Gram-negative pathogens. WCK-4234 can be used for the research of gram-negative bacterial infections and β-lactamase-mediated carbapenem-resistant bacterial infections .

HY-U00380

Tigemonam	Antibiotic Beta-lactamase Bacterial	Infection
Tigemonam is an orally active monobactam antibiotic with a K_i of 0.86 μM against Enterobacter cloacae P99 β-lactamase and 50.8 μM against Escherichia coli TEM-1 β-lactamase. Tigemonam binds to penicillin-binding proteins 1a, 3, and 4, inhibits bacterial cell wall synthesis, and exhibits bactericidal activity against aerobic gram-negative bacteria including Enterobacteriaceae, Haemophilus influenzae, and Neisseria gonorrhoeae. Tigemonam resists hydrolysis by multiple β-lactamase enzymes, reduces bacterial load in systemic, pyelonephritic, lung, and thigh muscle infections in rodents, and shows minimal difference between minimum inhibitory and bactericidal concentrations. Tigemonam can be used for the research of gram-negative bacterial infections, acute pyelonephritis, lung infection, and thigh muscle infection .

HY-16955

Plazomicin ACHN 490	Antibiotic Bacterial	Infection Inflammation/Immunology
Plazomicin (ACHN 490) is a semi-synthetic aminoglycoside Antibiotic. Plazomicin acts as a substrate for Aminoglycoside acetyltransferase and Aminoglycoside phosphotransferase. Plazomicin is not modified by various common aminoglycoside-modifying enzymes. Plazomicin selectively inhibits MATE2-K. Plazomicin exhibits activity against multidrug-resistant bacteria, including carbapenem-resistant Enterobacterales .

HY-176519

ANT2681	Beta-lactamase Bacterial	Infection
ANT2681 is a potent NDM inhibitor with a K_i value of 0.04 μM against NDM-1. ANT2681 also inhibits other MBLs, such as VIM-1 and IMP-1 with K_i values of 0.63 μM and 3.81 μM, respectively. ANT2681 can be used in combination with Meropenem (HY-13678) to inhibit infections caused by NDM-producing Enterobacteriaceae .

HY-171112

KSP-1007	Beta-lactamase Bacterial	Infection
KSP-1007 is a bicyclic boronate-based broad-spectrum β-lactamase inhibitor. KSP-1007 can effectively inhibit class A, B, C and D β-lactamases, including serine-type, metallo-type (such as NDM, VIM, IMP) and Acinetobacter baumannii OXA-type enzymes. KSP-1007 can enhance the antibacterial activity of Meropenem (HY-13678), reduce its MIC value, and be effective against carbapenemase-producing Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. KSP-1007 can be used for the research of bacterial infection .

HY-106095

DQ 2556	Antibiotic Bacterial Penicillin-binding protein (PBP)	Infection
DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins .

HY-W743473

Cefetamet-d3 Ro 15-8074-d₃; Deacetoxycefotaxime-d₃	Isotope-Labeled Compounds Bacterial Antibiotic Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-A0111A

Cefetamet sodium Ro15-8074/001; Deacetoxycefotaxime sodium	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) sodium is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet sodium binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet sodium has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet sodium kills and lyses Treponema pallidum. Cefetamet sodium can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-A0111B

Cefetamet hydrochloride Ro 15-8074 hydrochloride; Deacetoxycefotaxime hydrochloride	Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Ro 15-8074) hydrochloride is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet hydrochloride binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet hydrochloride has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet hydrochloride kills and lyses Treponema pallidum. Cefetamet hydrochloride can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-A0111R

Cefetamet (Standard) Ro 15-8074 (Standard); Deacetoxycefotaxime (Standard)	Reference Standards Antibiotic Bacterial Penicillin-binding protein (PBP) Drug Metabolite	Infection
Cefetamet (Standard) is the analytical standard of Cefetamet (HY-A0111). This product is intended for research and analytical applications. Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

HY-111034

CGP 31523A	Antibiotic Bacterial	Infection
CGP 31523A is a broad-spectrum aminothiazole cephalosporin. CGP 31523A exhibits potent inhibitory effects on Enterobacteriaceae, Neisseria, Haemophilus influenzae, and Streptococcus (except Enterococcus faecalis), among others. CGP 31523A can be hydrolyzed by the common Escherichia coli type Ic β-lactamase, but is stable against the Ia type enzyme. CGP 31523A is neither an effective β-lactamase inhibitor nor does it induce the production of β-lactamase. CGP 31523A can be used for studying infections caused by Gram-negative bacteria (including drug-resistant strains) .

HY-125604A

WCK-4234 free base	Beta-lactamase Bacterial	Infection Inflammation/Immunology
WCK-4234 free base is a diazabicyclooctane β-lactamase inhibitor and susceptibility restorer. WCK-4234 free base lacks direct antibacterial activity. WCK-4234 free base inhibits class A, C, D β-lactamases and extended-spectrum β-lactamases to potentiate Imipenem (HY-B1369A) and Meropenem (HY-13678) activity against Gram-negative pathogens. WCK-4234 free base can be used for the research of gram-negative bacterial infections and β-lactamase-mediated carbapenem-resistant bacterial infections .

Cat. No.	Product Name	Chemical Structure

HY-W743473

Cefetamet-d3
Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

Cefetamet-d3

Cefetamet-d₃ (Ro 15-8074-d₃; Deacetoxycefotaxime-d₃) is the deuterium labeled Cefetamet (HY-A0111). Cefetamet (Ro 15-8074) is a cephalosporin antibiotic and the active metabolite of Cefetamet pivoxil (HY-B1894A). Cefetamet binds to bacterial penicillin-binding protein (PBP) (IC₅₀ for PBP3 in Escherichia coli W3110 is 2.5 μg/mL). Cefetamet has significant activity against Gram-negative bacteria such as Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, as well as Gram-positive bacteria such as Streptococcus. Cefetamet kills and lyses Treponema pallidum. Cefetamet can be used in the research of respiratory tract, urinary tract, ear, nose and throat infections, and syphilis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.